Mitozolomide activity on human cancer cells in vitro.
The growth inhibitory effects, the reduction of [3H]-TdR incorporation and the perturbation of the cell cycle induced by the new agent mitozolomide on the M14 human melanoma cell line and on the SW626 human ovarian cancer cell line were compared to those produced by BCNU. Flow cytometry showed an interesting difference: at the high concentration mitozolomide induced an accumulation of cells in S middle and S late-G2-M phase of the cell cycle whereas BCNU caused only a block in S late-G2-M. Further studies were aimed at investigating the susceptibility of freshly isolated human ovarian cancer cells to pharmacologically reasonable mitozolomide concentrations. Only in one out of 16 primary cultures of human ovarian cancers was mitozolomide able to induce cell cycle perturbation, suggesting that ovarian carcinoma cells may not be sensitive to this drug.
D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002330:Carmustine / Q000633:toxicity; D002453:Cell Cycle / Q000187:drug effects; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008545:Melanoma / Q000378:metabolism; D008875:Middle Aged; D008938:Mitosis / Q000187:drug effects; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; C040369:mitozolomide; D002330:Carmustine; D013936:Thymidine